不同人群抗HBV治疗的时机和药物选择

张烨琼; 罗秋敏; 王璐; 彭亮; 高志良

doi:10.3969/j.issn.1001-5256.2022.11.002

不同人群抗HBV治疗的时机和药物选择

DOI: 10.3969/j.issn.1001-5256.2022.11.002

张烨琼¹,
罗秋敏¹,
王璐²,
彭亮^1, , ,,
高志良¹

1.
中山大学附属第三医院感染性疾病科, 广州 510630
2.
滨州医学院第二临床医学院，山东烟台 264003

利益冲突声明: 所有作者均声明不存在利益冲突。

作者贡献声明: 张烨琼负责文章撰写；罗秋敏、王璐负责文献检索；彭亮负责文章修改及审校；高志良负责文章整体指导。

详细信息

通信作者:
彭亮，pliang@mail.sysu.edu.cn

计量
- 文章访问数: 901
- HTML全文浏览量: 221
- PDF下载量: 216
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-22
- 录用日期: 2022-07-26
- 出版日期: 2022-11-20

Anti-HBV therapy timing and drug selection in various populations

1.
Department of infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
2.
Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong 264003, China

More Information

Corresponding author: PENG Liang, pliang@mail.sysu.edu.cn(ORCID: 0000-0001-6184-5750)

摘要

摘要: HBV感染仍是威胁人类健康的重大疾病，抗HBV治疗是极其重要的减少乙型肝炎威胁的手段。近年来，关于抗HBV治疗的时机以及药物选择仍无统一的意见。本文就不同人群抗HBV治疗的时机和药物的选择进行了综述。
- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 抗病毒药
Abstract: Hepatitis B virus (HBV) infection is still a serious disease threatening human health. Anti-HBV treatment is an extremely important means to reduce the threat of hepatitis B. In recent years, there has been no consensus on the timing and drug selection of anti-HBV therapy. The timing and drug selection of anti-HBV therapy in various populations are discussed in this article.
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Antiviral Agents

HTML全文

参考文献(36)

[1]	LIU J, LIANG W, JING W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238. DOI: 10.2471/BLT.18.219469.
[2]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[3]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[4]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[5]	KUMAR M, SARIN SK, HISSAR S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT[J]. Gastroenterology, 2008, 134(5): 1376-1384. DOI: 10.1053/j.gastro.2008.02.075.
[6]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
[7]	LIU J, WANG J, YAN X, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal alt and detectable HBV DNA in absence of liver fibrosis[J]. Hepatol Commun, 2022, 6(4): 855-866. DOI: 10.1002/hep4.1859.
[8]	MASON WS, GILL US, LITWIN S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J]. Gastroenterology, 2016, 151(5): 986-998.e4. DOI: 10.1053/j.gastro.2016.07.012.
[9]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[10]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[11]	CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study[J]. J Infect Dis, 2017, 216(11): 1407-1414. DOI: 10.1093/infdis/jix506.
[12]	LEE HW, KIM EH, LEE J, et al. Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase[J]. Clin Transl Gastroenterol, 2020, 11(3): e00140. DOI: 10.14309/ctg.0000000000000140.
[13]	JEON MY, KIM BK, LEE JS, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2021, 27(2): 295-304. DOI: 10.3350/cmh.2020.0216.
[14]	LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741.
[15]	WANG L, WU L, LI X, et al. Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial[J]. BMJ Open, 2021, 11(8): e048410. DOI: 10.1136/bmjopen-2020-048410.
[16]	CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044.
[17]	ZHU S, ZHANG H, DONG Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study[J]. J Hepatol, 2018, 68(6): 1123-1128. DOI: 10.1016/j.jhep.2018.01.037.
[18]	CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66(4): 1058-1066. DOI: 10.1002/hep.29213.
[19]	GAO WK, SHU YY, CHEN Y, et al. Effectiveness of Tenofovir Alafenamide in chronic hepatitis B patients with normal alanine aminotransferase and positive hepatitis B virus DNA[J]. J Clin Transl Hepatol, 2022, 10(1): 112-119. DOI: 10.14218/JCTH.2021.00131.
[20]	WANG FD, ZHOU J, ZHANG DM, et al. A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg-positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA[J]. Chin J Hepatol, 2022, 30(4): 389-394. DOI: 10.3760/cma.j.cn501113-20210705-00318. 王发达, 周静, 张冬梅, 等. 核苷(酸)类似物治疗丙氨酸转氨酶正常HBeAg阳性且HBV DNA高水平慢性乙型肝炎的有效性研究[J]. 中华肝脏病杂志, 2022, 30(4): 389-394. DOI: 10.3760/cma.j.cn501113-20210705-00318.
[21]	UDOMPAP P, KIM D, AHMED A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment[J]. Aliment Pharmacol Ther, 2018, 48(11-12): 1282-1289. DOI: 10.1111/apt.15020.
[22]	LAI KN, LI PK, LUI SF, et al. Membranous nephropathy related to hepatitis B virus in adults[J]. N Engl J Med, 1991, 324(21): 1457-1463. DOI: 10.1056/NEJM199105233242103.
[23]	CAI D, PAN C, YU W, et al. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials[J]. Medicine (Baltimore), 2019, 98(1): e13983. DOI: 10.1097/MD.0000000000013983.
[24]	LÓPEZ CENTENO B, COLLADO BORRELL R, PÉREZ ENCINAS M, et al. Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B[J]. Farm Hosp, 2016, 40(4): 279-286. DOI: 10.7399/fh.2016.40.4.10492.
[25]	AGARWAL K, FUNG SK, NGUYEN TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J]. J Hepatol, 2015, 62(3): 533-540. DOI: 10.1016/j.jhep.2014.10.035.
[26]	AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
[27]	OGAWA E, NOMURA H, NAKAMUTA M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7): 1578-1589. DOI: 10.1111/liv.14482.
[28]	FARAG MS, FUNG S, TAM E, et al. Effectiveness and renal safety of Tenofovir Alafenamide fumarate among chronic hepatitis B patients: Real-world study[J]. J Viral Hepat, 2021, 28(6): 942-950. DOI: 10.1111/jvh.13500.
[29]	LAMPERTICO P, BUTI M, FUNG S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 441-453. DOI: 10.1016/S2468-1253(19)30421-2.
[30]	de FRAGA RS, van VAISBERG V, MENDES L, et al. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review[J]. J Gastroenterol, 2020, 55(5): 496-514. DOI: 10.1007/s00535-020-01680-0.
[31]	NGUYEN MH, LIM JK, BURAK OZBAY A, et al. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B[J]. Hepatology, 2019, 69(3): 959-973. DOI: 10.1002/hep.30246.
[32]	YU MW, LIN CL, LIU CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: A large cohort study[J]. Gastroenterology, 2017, 153(4): 1006-1017.e5. DOI: 10.1053/j.gastro.2017.07.001.
[33]	SANTOS JR, SAUMOY M, CURRAN A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial[J]. Clin Infect Dis, 2015, 61(3): 403-408. DOI: 10.1093/cid/civ296.
[34]	LI ZB, LI L, NIU XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia[J]. Liver Int, 2021, 41(6): 1254-1264. DOI: 10.1111/liv.14786.
[35]	BYUN KS, CHOI J, KIM JH, et al. Tenofovir Alafenamide for drug-resistant hepatitis B: A randomized trial for switching from tenofovir disoproxil fumarate[J]. Clin Gastroenterol Hepatol, 2022, 20(2): 427-437.e5. DOI: 10.1016/j.cgh.2021.04.045.
[36]	ZHANG Y, LI Z, LUO Q, et al. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study[J]. Antivir Ther, 2022, 27 (2): 135965352210823. DOI: 10.1177/13596535221082399.